Opendata, web and dolomites


Improving the Treatment of Head and Neck Cancer without Additional Side Effects

Total Cost €


EC-Contrib. €






Project "HyperCollar3D" data sheet

The following table provides information about the project.


Organization address
postcode: 3029AK
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Project website
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-05-01   to  2018-09-30


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    SENSIUS B.V. NL (ROTTERDAM) coordinator 50˙000.00


 Project objective

Head and Neck (H&N) cancer is the 6th most frequent cancer and the average 5-year survival following the diagnosis is below 50%. Radiation therapy (at times combined with chemotherapy) is currently the most common method to tackle H&N cancer. Yet, its effectiveness goes hand in hand with its toxicity levels, and hence its side effects. Our mission at Sensius is making the treatment of H&N cancer more effective without undesirable additional side effects. And the key innovation to achieve this mission is hyperthermia. There are numerous scientific evidences that warming up the tumor to about 42 °C improves its sensitivity to the radiotherapy treatment. In fact, there are already multiple solutions of the market offering devices for hyperthermia working on several types of cancer, but not for H&N cancer. Our HyperCollar3D is the first device based on hyperthermia for H&N cancer. The HyperCollar3D has been tested by over 70 patients at the Erasmus Medical Center in Rotterdam with excellent results: patients have a 50% higher chance to be cured when hyperthermia is used as a complement of radiotherapy. These results have been validated by the scientific community, published on peer- reviewed medical journals and presented at scientific conferences. This innovation has a huge business potential: only in EU & USA markets we could have about 50,000 new users every year. Other manufacturers already commercialize hyperthermia solutions for cancer treatment, but none of them focuses on H&N cancer because this area is complicated to treat. The IP of the HyperCollar3D has been protected with a European patent. The team behind the HyperCollar3d is top notch: the five founders of Sensius are a mix of medical, technical, and business expertise and they together wield decades of experience in high-tech product development, marketing of medical technology, and medical solutions based on hyperthermia.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "HYPERCOLLAR3D" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "HYPERCOLLAR3D" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

AMBRPAY (2019)

Decentralized subscription payments with cryptocurrency

Read More  

Colourganisms (2020)

Microbial production of custom-made, pure and sustainable anthocyanins

Read More  

COPI (2020)

Carbon Offset Plug-in

Read More